FDA
-
-
-
-
-
-
-
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
-
-
-
-
-
-
-
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
-
-
-
-
-
-
-
bioAffinity Technologies Reports First Quarter 2023 Financial Results
326,907 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

